MADISON, Wis. – Voximetry, a pioneer in advanced dosimetry technology to enable personalized treatments for cancer patients, announced today its support for the Foundation for the National Institutes of Health (FNIH), working to establish dosimetry as an imaging biomarker. The Precision Dosimetry Imaging Biomarker (PDIB) project will establish dosimetry as a valuable imaging biomarker to improve patient outcomes by personalizing radiopharmaceutical therapies (RPT). Standardization is critical to enable the accurate and reliable absorbed dose calculations needed to accelerate development of the field.
“Voximetry is encouraged by the launch of the PDIB project, which will build the infrastructure and operational foundations for dosimetry-guided RPT, helping to establish a new standard of care,” said Fred Wilson, Vice President of Scientific Affairs. “This project is well aligned with our aim to make routine dosimetry a reality for every RPT provider and patient worldwide.”
This three-year, $4.9 million FNIH project launched in April 2025 brings together leading experts from government, academia, medical societies, patient advocacy groups, and industry to:
- Develop innovative tools to improve the reliability of radiation measurements throughout the treatment pathway.
- Harmonize imaging protocols and dose measurements to optimize consistency of patient treatment strategies.
- Create harmonized methods to foster cross-specialty collaboration and accelerate the development of new RPTs.
The project is led by the FNIH with Professor John Sunderland and Professor Stephen Graves at the University of Iowa acting as Principal Investigators.
During Phase 1, the PDIB project team will work with international standards laboratories including NIST, professional societies, academics, industry, and the FDA to develop harmonized protocols for measuring radioactivity, calibrating imaging systems, and calculating the amount of energy that the radiation delivers to the patient’s tumors and normal organs (the “absorbed dose”). This work is expected to develop a framework for incorporating existing tools into a standardized workflow for broad adoption, underpinning personalized treatments and leading to improved patient survival and quality of life. Importantly, the planned work will apply to all RPTs.
A subsequent Phase 2 of the project plans to use the standardized workflows in dose escalation clinical trials of RPTs in metastatic castrate-resistant prostate cancer (mCRPC) and neuroendocrine cancers to determine the absorbed radiation dose tolerance of normal organs. Currently, tolerance limits based on data from external beam radiotherapy (EBRT) are used and it is well understood that these do not apply directly to RPTs. Combined with existing treatment regimens based on fixed radioactivity administration, this has likely resulted in gross and systematic undertreating of many patients. Voximetry’s Torch software, the industry’s most accurate and only GPU accelerated, full Monte Carlo dose assessment technology will be made available for use throughout the clinical trials.
The Biomarkers Consortium, managed by the FNIH, leads cross-sector efforts to validate and seek regulatory endorsement of biomarkers to accelerate the development of new therapeutics and health technologies in a pre-competitive environment. For more information, please visit www.fnih.org/our-programs/biomarkers-consortium/.
About Torch
Torch® is the industry’s most accurate and only GPU-accelerated, Full Monte Carlo dose assessment software. Torch is a proprietary product developed by Voximetry and approved for clinical use by the FDA. Torch design and development continues to be supported by the National Cancer Institute of the National Institutes of Health under Award Numbers R43CA221491 and 2R44CA291564. The product is solely the responsibility of Voximetry and does not represent the official views of the National Institutes of Health. Torch design and development was supported by grants from the University of Wisconsin-System SBIR Advance Matching Grant Fund through its partnership with the Wisconsin Economic Development Corporation.
About Voximetry
Voximetry is committed to enabling personalized and effective theranostic treatment options for patients worldwide through wide-ranging collaboration, deep scientific expertise, and technology-forward progress. Based in Madison, Wisconsin, Voximetry is a Healthtech software and services company pioneering patient-specific radiopharmaceutical treatment planning (RPT) in advanced stage cancer patients.
About the FNIH Biomarkers Consortium
Established by Congress in 1990 to support the mission of the National Institutes of Health (NIH), the Foundation for the NIH (FNIH) builds public-private partnerships that connect leading biomedical scientists at the NIH, life sciences companies, foundations, academia, and regulatory agencies. Through team science, we solve complex health challenges and accelerate breakthroughs for patients.